Blueline Advisors’s AbbVie ABBV Stock Holding History

Blueline Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$12.8K	Hold	51	–	–	0.01%	176
2026 Q1	$11.1K	Hold	51	–	–	0.01%	163
2025 Q4	$11.7K	Buy	+51	New	+$11.6K	0.01%	160

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Blueline Advisors's ABBV Position: Q2 2026 in Review

Blueline Advisors held its AbbVie (ABBV) position steady in Q2 2026 at 51 shares worth $12.8K. The position accounts for 0.01% of the portfolio, ranked #176.

Blueline Advisors first reported a position in ABBV in Q4 2025 and has held it in 3 quarters since. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Blueline Advisors held 51 shares of AbbVie worth $12.8K as of Q2 2026.
Blueline Advisors left its AbbVie share count unchanged in Q2 2026.
AbbVie made up 0.01% of Blueline Advisors's portfolio in Q2 2026, its #176 holding.
Blueline Advisors first reported a position in AbbVie in Q4 2025 and has held it in 3 quarters since.
4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Blueline Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.